A Phase III Randomized, Multicentre, Double Blind, Active Controlled Trial to Compare the Efficacy and Safety of Two Different Anagrelide Formulations in Patients With Essential Thrombocythaemia

Results from this phase III study suggest that the use of extended-release anagrelide in the treatment of essential thrombocythemia may offer reduced dose frequency and potentially less severe adverse events, versus non-extended release formation. The mean screening platelet counts—the trial’s primary endpoint—were 822 x 109/L (95% CI, 707-936 x 109/L) for the extended-release group compared with 797 x 109/L (95% CI, 708-883 x 109/L) for the non-extended release group.

British Journal of Haematology